

## PRESS RELEASE

# Hansa Biopharma appoints new Chief Executive Officer

Lund, Sweden, 24 April 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the Company.

"On behalf of the Board of Directors, I would like to extend our gratitude to Søren for his leadership and significant contribution to the company during his tenure. Under his guidance, Hansa has evolved from a clinical-stage company into a commercial-stage biopharmaceutical organization, navigating both transformative progress and substantial challenges. We deeply appreciate Søren's commitment to the Company and wish him every success in his future endeavors," said Peter Nicklin, Chairman of the Board, Hansa Biopharma. "With the appointment of Renée as CEO, Hansa is entering a new phase of growth and development. Renée brings extensive experience in both the biopharmaceutical and financial sectors, and her proven leadership will be instrumental in advancing the Company's strategic positioning. The Board is confident that she is the right person to successfully lead Hansa through this next chapter, and we look forward to working closely with her."

Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden and the U.S. During her tenure, the company successfully launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy in the U.S. and until it was acquired by Asahi Kasei Corporation of Japan in September 2024. Prior to that, Aguiar-Lucander had a long and successful career in the healthcare investment sector, holding senior roles in funds such as Omega Funds and 3i Group.

Aguiar-Lucander said, "I am delighted and honored to take up the position of CEO of Hansa during this exciting and challenging times. I hope to bring relevant perspectives from my previous roles, both with regards to capital raising and management, as well as insights regarding regulatory, commercial preparation and launch dynamics. I look forward to working with the team and Board to ensure Hansa's future success."

In light of these changes, Hansa's Q1 2025 interim results conference call, scheduled for 14:00 CEST/8:00am EDT later today, will be hosted by Peter Nicklin (Chairman of the Board), Evan Ballantyne (CFO) and Hitto Kaufmann (Chief R&D Officer), and will be joined by Renée Aguiar-Lucander.

*This is information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 7:00 CEST on 2025-04-24.*

--- ENDS ---

### Contacts for more information:

Evan Ballantyne, Chief Financial Officer  
[IR@hansabiopharma.com](mailto:IR@hansabiopharma.com)

Stephanie Kenney, VP Global Corporate Affairs  
[media@hansabiopharma.com](mailto:media@hansabiopharma.com)

### Notes to editors

### About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](http://www.hansabiopharma.com) and follow us on [LinkedIn](#).

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.